
Restore Technologies is developing a portfolio of novel central nervous system (CNS) stimulation-based solutions to treat a range of serious health conditions.
Market:
Replacing mechanical ventilation represents an addressable U.S. market of ~$12B+ in 2018. Over 70-80% of patients with acute respiratory failure are due to a neurogenic cause and are potentially addressable with Restore’s respiratory pacemaker. Furthermore, total indirect costs from mechanical ventilation exceeds $800B annually in the U.S. suggesting a significant positive health economic impact from using Restore’s respiratory pacemaker.Technology:
Restore’s technology works by stimulating the CNS in a proprietary way to restore neurogenic, dysregulated autonomic functions such as respiration, bladder function, among others. Our first therapeutic device is a respiratory pacemaker which can help patients regain neurological control of their respiration. Restore’s respiratory pacemaker is a disruptive technology with potential to eventually supplant the use of mechanical ventilation, which is an antiquated, highly morbid and high cost solution. Restore’s novel approach has been validated in human patients and can be administered non-invasively or via a minimally invasive implant. Beyond respiration, the company is developing solutions to restore other autonomic functions.Advantages:
- Non-invasive
- Automated
- Responds to respiratory drive changes
- Adapts to physiological activity
Development Stage:
- Pre-Clinical
Patents Issued:
- Restore holds several exclusive option agreements with UCLA
Select Publications:
- Coming Soon
Contact:
Email: info@restore-technologies.comGraduated in 2023
Graduated Companies
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Bluefin Foods
- CarbonBuilt
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete-AI
- Craytex
- CytoLumina
- DARTS Sciences
- Electronucleics
- EP Dynamics
- Ferrologix
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- Millibatt
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoClear
- NanoElectronic Imaging
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Polyradiant
- Qwixel Therapeutics
- Restore Technologies
- Sardona Therapeutics
- SELFA
- Sixal
- Spectradyne Particle Analysis
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- Vivibaba
- Zenomics
- Back to Portfolio